Wolverine Blend (BPC-157 / TB-500) (10 mg Vial) Dosage Protocol
Wolverine Blend combines BPC-157 and TB-500 in a single vial — the two most-studied tissue-repair peptides, working through complementary mechanisms. This page covers the 10 mg vial.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
10 mg total blend reconstituted to 3.0 mL
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
Route: Subcutaneous injection | Frequency: Once daily
| Week | Daily Dose (Total Blend) | Each Peptide | U-100 Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | ~250 mcg each | 15 units (0.15 mL) |
| Weeks 3–4 | 666 mcg (0.67 mg) | ~333 mcg each | 20 units (0.20 mL) |
| Weeks 5–8 | 1,000 mcg (1.0 mg) | ~500 mcg each | 30 units (0.30 mL) |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject the diluent slowly down the inside wall of the vial.
- Gently swirl until dissolved. Do not shake.
- Label with the compound, concentration, and preparation date; refrigerate at 2–8 °C (36–46 °F) and protect from light.
Advanced / Loading Phase (Optional)
This community-reported calculation uses a higher total blend amount during the first four weeks.
Route: Subcutaneous injection | Frequency: Once daily
| Phase | Daily Dose (Total Blend) | Each Peptide | U-100 Units (mL) |
|---|---|---|---|
| Loading (Weeks 1–4) | 1,500 mcg (1.5 mg) | ~750 mcg each | 45 units (0.45 mL) |
| Maintenance (Weeks 5–8) | 1,000 mcg (1.0 mg) | ~500 mcg each | 30 units (0.30 mL) |
Note: The advanced calculation consumes peptide supplies faster. It is included to preserve the established family schedule and is not a validated human regimen.
Research reference only: These rows translate the established community-reported family schedule into the 10 mg vial concentration. Published BPC-157 animal work, human thymosin beta-4 trials, and analytical TB-500 studies do not validate this premixed subcutaneous regimen.
Supplies Needed
Plan based on the displayed 4–8 week standard / gradual calculation sequence.
| Item | Quantity |
|---|---|
| BPC-157 + TB-500 10 mg blend vials | 4 weeks: 2 vials (16.324 mg calculated total) 6 weeks: 4 vials (30.324 mg calculated total) 8 weeks: 5 vials (44.324 mg calculated total) |
| U-100 insulin syringes | 4 weeks: 28 syringes 6 weeks: 42 syringes 8 weeks: 56 syringes |
| Bacteriostatic water (10 mL bottles) | Use 3.0 mL per vial. 4 weeks: 6 mL → 1 bottle 6 weeks: 12 mL → 2 bottles 8 weeks: 15 mL → 2 bottles |
| Alcohol swabs | Two per administration: one for the vial stopper and one for the injection site. 4 weeks: 56 swabs → 1 × 100-count box 6 weeks: 84 swabs → 1 × 100-count box 8 weeks: 112 swabs → 2 × 100-count boxes |
Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
BPC-157 provides local cytoprotection, angiogenesis, and tendon-cell migration. TB-500 provides systemic actin regulation and cell migration. The two work through complementary mechanisms; they are commonly combined in connective-tissue research protocols.
Potential Benefits & Side Effects
Potential Benefits
- Synergistic tissue-repair effects.
- Established research-grade combination.
- Suitable for both local and systemic protocols.
Side Effect Profile
- Combined profile of components.
- Injection-site reactions.
- Generally well-tolerated.
Lifestyle Factors
- Pair with appropriate physical therapy.
- Adequate protein and collagen-supportive nutrients.
- Avoid NSAIDs during early-phase repair.
Injection Technique
- Subcutaneous, abdomen/thigh/upper arm. Rotate sites if dosing twice daily.